Program
GB268
A development code.
Its studies are mostly in Breast Neoplasms, led by 2 companies.
Furthest: phase 2, since Mar 16, 20252 company-led studies, 2 open or runningNext primary completion: Mar 2027 (phase 1)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Edding Genor Group | 11 open or running | phase 1since Mar 16, 2025 | Mar 16, 2025 | Mar 2027phase 1 · NCT06934616 |
| Eddingpharm (Zhuhai) | 11 open or running | phase 2since Jul 23, 2026 | Jul 23, 2026 | Aug 1, 2029phase 2 · NCT07738341 |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Mar 16, 2025First study: phase 1 study in Diabetes Mellitus, Insulin-Dependent, 12New to Edding Genor GroupEdding Genor Group · NCT06934616 · 330 planned
- Jul 23, 2026Eddingpharm (Zhuhai)'s first study: phase 2 study in Breast NeoplasmsNew to Eddingpharm (Zhuhai)Eddingpharm (Zhuhai) · NCT07738341 · 270 planned
Ahead
- Mar 2027Primary completion: phase 1 study in Diabetes Mellitus, Insulin-Dependent, 12Edding Genor Group · NCT06934616
- Aug 1, 2029Primary completion: phase 2 study in Breast NeoplasmsEddingpharm (Zhuhai) · NCT07738341
TargetBeta
CTLA4 →read by rule
“GB268 is a tri-specific antibody targeting PD-1, CTLA-4, and VEGF.”study text, by rule · the study
Other programs on CTLA4
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| tremelimumabrule | AstraZeneca | phase 3 | 47 |
| cadonilimabrule | Akeso | phase 3 | 45 |
| Iparomlimab/Tuvonralimabrule | Qilu Pharmaceutical | phase 3 | 22 |
| volrustomig | AstraZeneca | phase 3 | 19 |
| Anti-CTLA-4 Monoclonal Antibody SHR-8068rule | Jiangsu HengRui Medicine | phase 3 | 16 |
| erfonrilimabrule | Alphamab Oncology | phase 3 | 14 |
| Anti-CTLA-4 Monoclonal Antibody IBI310rule | Innovent Biologics | phase 3 | 11 |
| gotistobartrule | oncoc4-inc | phase 3 | 5 |
| zalifrelimabrule | Agenus | phase 2 | 6 |
| porustobartrule | harbour-biomed-guangzhou-co-ltd | phase 2 | 5 |
| lorigerlimabrule | MacroGenics | phase 2 | 4 |
| Anti-PD-1/Anti-CTLA-4/Anti-VEGF Trispecific Antibody HC010rule | hc-biopharma-inc | phase 2 | 2 |
Studies
All 2 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07738341Breast Neoplasms | 2 | Not yet recruiting | Eddingpharm (Zhuhai) | Aug 1, 2029 | 270 |
| NCT06934616Diabetes Mellitus, Insulin-Dependent, 12 | 1 | Not yet recruiting | Edding Genor Group | Mar 2027 | 330 |
How it is read
Names in the registry
- “GB268”, 2 entries
Codes read as this program: GB268.
Conditions, from the studies’ own filings
- Breast Neoplasms, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.